NCT05715281View on ClinicalTrials.gov

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

October 15, 2026

Study Completion Date

October 15, 2026

Conditions
Advanced Rare Malignant Solid NeoplasmRare Malignant Solid NeoplasmRefractory Rare Malignant Solid Neoplasm
Interventions
BIOLOGICAL

Atezolizumab

Given IV

PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Echocardiography Test

Undergo ECHO

DRUG

Tiragolumab

Given IV

Trial Locations (3)

20892

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

National Institutes of Health Clinical Center, Bethesda

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT05715281 - Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial | Biotech Hunter | Biotech Hunter